MedicaidPrior AuthHigh impact
Darzalex® (daratumumab) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has established a new prior authorization policy for Darzalex (daratumumab) intravenous solution effective March 1, 2026. This policy requires prior authorization for all Darzalex treatments for multiple myeloma patients, with specific criteria based on transplant eligibility, combination therapies, and prior treatment history.
Action Required
Before March 1, 2026: Billing team must implement prior authorization requirements for all Darzalex (daratumumab) intravenous solution claims for Humana Medicaid Indiana patients. Update billing system to flag these cases for prior auth review. Providers must document multiple myeloma diagnosis, transplant eligibility status, specific combination therapy regimens, and prior treatment history. Claims submitted without prior authorization will be denied.